Covetrus to sell diagnostics subsidiary to Heska for US$125 million

Covetrus is divesting itself of its Scil Animal Care business to Heska Corp. in an all-cash deal worth US$125 million.

Subject to customary closing conditions, the transaction is expected to close in the next 60 to 90 days. Headquartered in Germany, Scil is a veterinary diagnostics company that distributes in 24 countries, including Canada.

The agreement also includes a commercial relationship between Covetrus and Heska tied to ongoing logistics support for the latter’s family of …

Covetrus to sell diagnostics subsidiary to Heska for $125 million

Covetrus is divesting itself of its Scil Animal Care business to Heska Corp. in an all-cash deal worth US$125 million.

Subject to customary closing conditions, the transaction is expected to close in the next 60 to 90 days. Headquartered in Germany, Scil is a veterinary diagnostics company that distributes in 24 countries.

The agreement also includes a commercial relationship between Covetrus and Heska tied to ongoing logistics support for the latter’s family of diagnostic products, …

Elanco and Aratana Therapeutics finalize deal to merge

Elanco Animal Health has acquired Aratana Therapeutics.

Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders.

“Aratana’s strong position in the specialty market—with its current portfolio and pipeline—complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” says Jeff Simmons, president and chief executive officer of Elanco. “This deal furthers Elanco’s value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians …

Elanco and Aratana Therapeutics finalize deal to merge

Elanco Animal Health has acquired Aratana Therapeutics.

Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders.

“Aratana’s strong position in the specialty market—with its current portfolio and pipeline—complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” says Jeff Simmons, president and chief executive officer of Elanco. “This deal furthers Elanco’s value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians …